arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

FILANA THERAPEUTICS, INC.

FLNA
$0.45 ▼ -0.11 (-19.99%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

FILANA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -12.9% ↗
FCF / Share None
Trailing P/E —
Price / Book 0.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.96M
↓ -28.1% —
Net Income Profit after all expenses
$-10.33M
↑ +55.9% —
Operating Margin Operating profit as % of sales
-39.6%
↓ -143.4% —
FCF / Share Free cash flow per share
$-0.13
↓ -27.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
7
Cash Quality ↓
34

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 67 quarters